All In Biotech

NDA 050356 · Ph Health

Coly-Mycin S

Colistin Sulfate, Hydrocortisone Acetate, Neomycin Sulfate, Thonzonium Bromide · Otic

Last checked: Nov 19, 2026Latest source record: Jan 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1962

May 17, 1962

Approved uses

1

Original approval plus efficacy supplements

Registered trials

94

39 Phase 3, 14 recruiting

FAERS reports

2

2 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 1, 2024.

INDICATIONS AND USAGE Cortisporin ® TC Otic is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 17, 1962 Original approval
1 products under this application
  • COLY-MYCIN S · COLISTIN SULFATE EQ 3MG BASE/ML; HYDROCORTISONE ACETATE 10MG/ML; NEOMYCIN SULFATE EQ 3.3MG BASE/ML; THONZONIUM BROMIDE 0.5MG/ML · SUSPENSION/DROPS, OTIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Colistin" as an intervention, any sponsor and status, largest first.

All 94 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthenia1
  • central nervous system lymphoma1
  • colitis1
  • dehydration1
  • diarrhoea1
  • dizziness postural1
  • dysstasia1
  • endophthalmitis1
  • fatigue1
  • general physical health deterioration1
  • malignant neoplasm progression1
  • nausea1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20221
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 376 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.